Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced
10:36am, Monday, 12'th Jan 2026
Shares of Insmed rise after it tops FY25 sales forecasts, led by strong Brinsupri uptake, and outlines 2026 guidance and pipeline milestones.
Insider Selling: Insmed (NASDAQ:INSM) CFO Sells $293,767.46 in Stock
05:58am, Sunday, 11'th Jan 2026
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CFO Sara Bonstein sold 1,678 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $175.07, for a
Insmed (NASDAQ:INSM) CFO Sells $252,023.99 in Stock
05:20am, Sunday, 11'th Jan 2026
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CFO Sara Bonstein sold 1,447 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $174.17, for a tot
Insider Selling: Insmed (NASDAQ:INSM) Insider Sells $183,401.01 in Stock
05:20am, Sunday, 11'th Jan 2026
Insmed, Inc. (NASDAQ: INSM - Get Free Report) insider Michael Alexander Smith sold 1,053 shares of the business's stock in a transaction on Thursday, January 8th. The stock was sold at an average pric
Insmed (NASDAQ:INSM) COO Sells $247,688.57 in Stock
05:20am, Sunday, 11'th Jan 2026
Insmed, Inc. (NASDAQ: INSM - Get Free Report) COO Roger Adsett sold 1,429 shares of the firm's stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $
Insmed (NASDAQ:INSM) CFO Sells $262,941.61 in Stock
05:20am, Sunday, 11'th Jan 2026
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CFO Sara Bonstein sold 1,517 shares of Insmed stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $173.33, for
Insmed (NASDAQ:INSM) Insider Sells $241,968.68 in Stock
05:20am, Sunday, 11'th Jan 2026
Insmed, Inc. (NASDAQ: INSM - Get Free Report) insider Michael Alexander Smith sold 1,396 shares of the business's stock in a transaction on Tuesday, January 6th. The shares were sold at an average pri
Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances
10:58am, Friday, 09'th Jan 2026
Insmed Inc (NASDAQ: INSM) on Friday outlined a commercial and clinical roadmap for 2026, highlighting strong momentum from its respiratory portfolio and a series of upcoming trial readouts and launche
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
07:00am, Friday, 09'th Jan 2026
— BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for Full-Year 2025— —ARIKAYCE® (amikacin
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
10:00am, Thursday, 08'th Jan 2026
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to co
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
11:48am, Tuesday, 06'th Jan 2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM). Such investors ar
INSM Stock Up 78% in 6 Months: Here's What You Need to Know
09:15am, Friday, 02'nd Jan 2026
Insmed shares surged on FDA and EU approvals of Brinsupri, strong uptake, and a growing pipeline which fueled optimism around its revenue outlook.
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
07:00am, Friday, 02'nd Jan 2026
BRIDGEWATER, N.J., Jan. 2, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
10:00am, Thursday, 01'st Jan 2026
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to co
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
12:37pm, Tuesday, 30'th Dec 2025
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM). Such investors ar
